Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
10
×
national blog main
clinical trials
new york top stories
boston blog main
national top stories
new york blog main
biotech
boston top stories
san diego blog main
san diego top stories
san francisco top stories
fda
indiana blog main
indiana top stories
national
san francisco blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
europe top stories
gene therapy
medicare
novartis
pfizer
roche
spark therapeutics
abbvie
alnylam pharmaceuticals
amgen
amicus therapeutics
What
drug
10
×
patients
10
×
fda
approved
bio
medicine
new
roundup
therapy
developers
disease
friday
help
market
medicines
pfizer
sets
today
type
acorda
acquisitions
advantages
ago
akcea
albert
alnylam
amyloidosis
approval
aren’t
atrophy
attr
available
bar
battle
bid
biggest
biologic
boehringer
bottleneck
bourla
Language
unset
unknown
Current search:
patients
×
drug
×
" life sciences "
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Medicare Drug Prices, FDA Moves, Gene Therapy News & More
@xconomy.com
5 years ago
Virtual Physical Therapy Firms Reflexion and MindMaze Probe Markets
@xconomy.com
6 years ago
Fixing the Clinical Trial Bottleneck by Making Patients a Priority